| PBP | penicillin-binding protein; porphyrin biosynthesis pathway; prostate-binding protein; pseudobulbar p... |
|---|---|
| pros | prostate, prostatic |
| PSA | parasternal short axis; pleomorphic salivary gland adenoma; polyethylene sulfonic acid; polysacchari... |
| PSAD | prostate-specific antigen density |
| TRPM | testosterone-repressed prostate message |
| GSD I | Glycogen storage diseases type I |
|---|---|
| HCD | Heavy chain diseases |
| ICD9CM | International Classification of Diseases 9th Revision Clinical Modification |
| ICD-9 CM | International Classification of Diseases, Ninth Revision, Clinical Modification |
| LSD | Lysosomal storage diseases |
| anti-inflammatory agent, steroidal | Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents. (12 Dec 1998) |
|---|---|
| anti-inflammatory agent, topical | Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application. (12 Dec 1998) |
| macrophage inflammatory protein | <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other. They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells. They most likely also play a significant role in respiratory tract defenses. (20 Sep 2002) |
| pelvic inflammatory disease | <disease> An inflammatory process that results from other pelvic diseases, may result from gonorrhoea, chlamydia, ovarian cystic disease or postpartum infections. (27 Sep 1997) |
| chronic inflammatory demyelinating polyneuropathy | An uncommon, acquired, demyelinating sensorimotor polyneuropathy, clinically characterised by insidious onset, and slow evolution, (either steady progression or stepwise), and chronic course; symmetrical weakness is a predominant symptom, often involving proximal leg muscles, accompanied by paresthesias, but not pain; CSF examination shows elevated protein, while electrodiagnostic studies reveal evidence of a demyelinating process, primarily conduction slowing rather than block; sometimes responds to prednisone. (05 Mar 2000) |
| chronic inflammatory polyneuropathy | <neurology, pathology> A disorder that involves the slow progressive (or recurrent) inflammation of multiple nerves. Loss of movement and sensation are common findings. The exact cause is related to an abnormal immune response. The acute form of this illness is known as Guillain-Barre syndrome. Treatment often includes systemic corticosteroids or chemotherapeutic agents to suppress the immune system. Prognosis is variable. Origin: Gr. Pathos = disease (27 Sep 1997) |
| non-steroidal anti-inflammatory | <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions. Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate. A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity. Acronym: NSAID (05 May 2002) |
| non-steroidal anti-inflammatory drug | <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions. Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate. A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity. Acronym: NSAID (05 May 2002) |
| desquamative inflammatory vaginitis | An acute inflammation of the vagina of unknown cause, characterised by grayish pseudomembrane, free discharge, and easy bleeding on trauma; the discharge contains pus and immature epithelial cells, although oestrogen levels are normal. Vaginitis emphysematosa, vaginitis characterised by accumulation of gas in small connective tissue spaces lined by foreign-body giant cells. Synonym: pachyvaginitis cystica, vaginitis cystica. (05 Mar 2000) |
| disease, pelvic inflammatory | Despite its seeming lack of gender, this term is applied to women only. PID refers exclusively to ascending infection of the female genital tract above the cervix. (12 Dec 1998) |
| inflammatory | <pathology> Inflammation is the reaction of living tissues to injury, infection or irritation. Inflamed tissues are characterised by pain, swelling, redness and heat. Anything that stimulates the inflammatory response is said to be inflammatory. See: inflammation. (11 Jun 1998) |
| inflammatory bowel disease | <disease> A general term that encompasses several disease processes, most commonly, ulcerative colitis and Crohn's disease. (27 Sep 1997) |
| inflammatory carcinoma | <tumour> Carcinoma of the breast presenting with oedema, hyperaemia, tenderness, and rapid enlargment of the breast; microscopically, there is extensive invasion of dermal lymphatics by the carcinoma. (05 Mar 2000) |
| inflammatory corpuscle | A cell present in an exudate that assists in the organization of new tissue. Synonym: exudation cell, inflammatory corpuscle, plastic corpuscle. (05 Mar 2000) |
| inflammatory fibrous hyperplasia | Overgrowth of tissue in the mucobuccal or labial fold, induced by chronic trauma from ill-fitting dentures. Synonym: denture hyperplasia, epulis fissuratum. (05 Mar 2000) |